BGNE

BeiGene Share Price

346.91
-6.08 (-1.72%)
Upgrade to Real-Time
Afterhours (Closed)
346.91
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Basic
Monthly Subscription
for only
$33.03
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
VAT not included
Company Name Stock Ticker Symbol Market Type
BeiGene Ltd BGNE NASDAQ Depository Receipt
  Price Change Change Percent Stock Price Last Traded
-6.08 -1.72% 346.91 20:00:00
Open Price Low Price High Price Close Price Prev Close
355.39 346.42 357.95 346.91 352.99
Bid Price Ask Price Spread News
310.00 380.00 70.00 1 2
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
3,485 118,274  350.77  41,486,900 160,057 155.16 - 388.97
Last Trade Time Type Quantity Stock Price Currency
16:33:55 71  346.91 USD

BeiGene Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
 31.92B 92.01M 81.36M  308.87M  - -19.00 -25.20
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
-  - - -189.34k 0.90%

more financials information »

News BeiGene

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

BGNE Historical

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.0%
1 Month0.000.000.000.0000.000.0%
3 Months0.000.000.000.0000.000.0%
6 Months0.000.000.000.0000.000.0%
1 Year0.000.000.000.0000.000.0%
3 Years0.000.000.000.0000.000.0%
5 Years0.000.000.000.0000.000.0%

BeiGene Ltd is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1.


Your Recent History
NASDAQ
BGNE
BeiGene
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.